83-2271-17　［受注停止］KRIBIOLISA Davalintide ELISA 1 x 96 wells　KBI5007

特徴

• Description：Immunoassay for quantitative determination of Insulin Glargine in human serum and plasma
• Insulin Glargine is produced by recombinant DNA technology.
• It is an analogue of human insulin made by replacing the asparagine residue at position A21 of the A-chain with glycine and adding two arginine to the C-terminus （positions B31 and 32） of the B-chain.
• The resulting protein is soluble at pH 4 and forms micro- precipitates at physiological pH 7.4.
• Small amounts of insulin Glargine are slowly released from micro-precipitates giving the drug a long duration of action （up to 24 hours） and no pronounced peak concentration.
• About the kit：
• - Uses anti-idiotypic antibodies sourced from our vendor partner in the US, which ensures higher specificity, and low cross reactivity.
• - Recovery rates are between 85 - 115％
• - Ready to use with a standard protocol with break-apart pre-coated wells
• - Validated as per US FDA guidelines for Bioassays
• - Optimized for matrix effects to ensure higher sensitivity.
• - Shelf life： 1 year
• The method employs the quantitative sandwich enzyme immunoassay technique.
• In the first step, samples and standards are pipetted into microwells.
• If insulin Glargine is present in the samples or standards, it will form complex with Anti-insulin Glargine antibody, which is pre-coated onto microwells.
• In the second step, anti-Insulin Glargine HRP conjugate is pipetted and incubated.
• Free HRP conjugate will be removed by a washing step.
• In the third step, TMB substrate is added to microwells and color develops proportionally to the amount of Insulin Glargine present in the samples or standards.
• Color development is then stopped by addition of stop solution.
• Absorbance is measured at 450 nm.